Tumor Suppressor Par-4

Introduction
Part 1Chapter 1. Role of Par-4 in lung cancerChapter 2. Prostate apoptosis response-4 in nasopharyngeal carcinomaChapter 3. Role of Par-4 in Chemoresistance and targeted therapies in ovarian and endometrial cancersChapter 4. Regulation of Par-4 and role in GI tumorsChapter 5. Role of Par-4 in prostate cancerChapter 6. Activation of apoptosis by Par-4 in pancreatic cancerChapter 7. Role of Par-4 and GRP78 in GlioblastomaChapter 8. Role of Par-4 in breast cancer recurrenceChapter 9. Involvement of Par-4 in breast cancerChapter 10. Role of endogenous Par-4 in CLLChapter 11. Role of Par-4 in inhibition of TCL1 induced growthChapter 12. Par-4/THAP in survival of T-cell acute lympoblastic leukemia cellsChapter 13. Par-4 expression in cholangiocarcinomaChapter 14. Par-4 suppresses breast cancer growth and invasion of breast cancer cellsChapter 15. PAWR as direct SRC-1/HOXC11 suppression targetChapter 16. Par-4 cleavage is required for TNF induced apoptosisChapter 17. Par-4 secretagoguesChapter 18. Recombinant production and characterization of SACChapter 19. Anti-tumor effects of plant derived Par-4Chapter 20. Par-4 in Mycobacterium tuberculosis Infected Macrophages
Part 2 - Role in other DiseasesChapter 21. Role of Par-4 in ceramide inducible effects in neuronsChapter 22. Role of Par-4 in Alzheimers diseaseChapter 23. Dopamine signaling in association with induction of Par-4 protein expressionChapter 24. Par-4 (PAWR) in major depressive disorderChapter 25. Par-4 dependent apoptosis of islet beta cells in type 2 diabetesChapter 26. Par-4 in cardiac fibroblast senescenceChapter 27. Par-4 in ocular development and diseaseChapter 28. Par-4 in apoptosis during human salivary gland developmentChapter 29. Suppression of Par-4 protects human renal proximal tubule cells from apoptosisChapter 30. Lessons from knockout mice
Part 3 -  From Bench to BedsideChapter 31. Par-4 secretagogues in clinical trialsChapter 32. Potential of Par-4 as a therapeutic target

Vivek M. Rangnekar, Ph.D. is Professor and Alfred Cohen Chair in Oncology Research in the Department of Radiation Medicine and Associate Director of the Markey Cancer Center at the University of Kentucky. His laboratory studies the molecular cross-talk between oncogenes and tumor suppressor genes in an effort to tilt the balance in favor of tumor suppressor function. Dr. Rangnekar originally identified and discovered the tumor suppressor protein Par-4/PAWR in 1993.